Benserazide
Cognitive Impairment
University Hospital Bispebjerg and FrederiksbergSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Cognitive Impairment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivastigmine VA Office of Research and Development | Phase 4 | BB |
Namenda UNC Lineberger Comprehensive Cancer Center | Phase 3 | BB |
Egb 761® Ipsen | Phase 4 | BB |
Pioglitazone University of Colorado, Denver | Phase 4 | BB |
Choline Alfoscerate Chong Kun Dang Pharmaceutical | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Benserazide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →